Modafinil is a wakefulness-promoting medicine developed in France during research on compounds related to adrafinil. Its approved medical context includes excessive sleepiness associated with narcolepsy, obstructive sleep apnea and shift work sleep disorder. The page also reviews cognition under sleep loss and preliminary mood, fatigue and neurological research.
For broader research context on nootropic compounds, including comparative stacks, cycling considerations, and interaction notes, see the Complete Nootropic Cheat Sheet.
What Is Modafinil?
Modafinil is a wakefulness-promoting medicine classified as a eugeroic, a term referring to agents that promote alertness with comparatively limited broad-spectrum stimulation. It is approved by the United States Food and Drug Administration for excessive sleepiness associated with narcolepsy, obstructive sleep apnea or hypopnea syndrome, and shift work sleep disorder. In obstructive sleep apnea, it is intended as an adjunct to treatment of the underlying airway obstruction, such as continuous positive airway pressure, rather than as a replacement for definitive respiratory therapy. Modafinil is commonly supplied as an oral tablet, with typical clinical use involving once-daily administration under medical supervision.
The compound was developed in France during research into drugs related to the older stimulant adrafinil and was subsequently developed internationally by Lafon Laboratories. In the United States, modafinil is classified as a Schedule IV controlled substance because it has recognized medical value but also carries potential for misuse, psychological dependence, and diversion. Brand names have included Provigil, Modalert, Modvigil, and Alertec, although availability and regulatory status vary by country. Modafinil is not an over-the-counter supplement, and products sold through unregulated websites may contain incorrect doses, contaminants, or different active ingredients.
Quick Reference
Member reference tables summarize the compound's research parameters.
Randomized controlled trials support modafinil for improving objectively and subjectively measured daytime wakefulness in narcolepsy.
Residual Sleepiness in Obstructive Sleep Apnea
Used as an adjunct for residual excessive daytime sleepiness in appropriately treated obstructive sleep apnea; it does not replace airway therapy.
Shift Work Sleep Disorder
Clinical studies support improved wakefulness during scheduled night work in people with diagnosed shift work sleep disorder.
Cognition Under Sleep Loss
Supported Research
Sustained Attention During Sleep Deprivation
Laboratory and operational research indicates benefit for vigilance and alertness when performance is impaired by acute sleep deprivation.
Executive Function and Working Memory
Effects in rested healthy adults are variable, with systematic reviews finding modest task-dependent improvements rather than universal enhancement.
Mood and Psychiatric Adjunct Research
Preliminary Data
Depression-Related Fatigue
Adjunctive studies have examined fatigue and residual symptoms in major depression, but results are mixed and use requires psychiatric oversight.
Attention-Deficit/Hyperactivity Disorder
Trials have explored modafinil in ADHD, but it is not broadly approved for this indication and safety considerations limit routine use.
Neuroprotection and Fatigue States
Emerging Evidence
Neurologic Disease Fatigue
Research in fatigue associated with neurologic conditions has produced heterogeneous findings and does not establish a general therapeutic role.
Mechanistic Neuroprotection Studies
Preclinical work suggests effects on catecholamine, histamine, orexin, and glutamatergic systems; these findings are not proof of clinical neuroprotection.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below), not a personal dosing recommendation.
This member section describes parameters reported in the research literature.
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
This member section discusses research safety considerations and uncertainties.
The described verification process includes looking for an accessible COA tied to the exact lot number, with identity, assay, and impurity testing results.
Verified Marker
Independent HPLC or LC-MS Identity Testing
A credible report identifies modafinil using an appropriate analytical method and provides chromatographic or mass-spectrometric documentation.
Verified Marker
Third-Party Contaminant Screening
Verification should include heavy metals and relevant microbial or residual-solvent testing performed by an independent laboratory.
Acceptable Range
Accurate Capsule or Tablet Content
Finished-product testing should substantiate the labeled milligram amount and reasonable unit-to-unit dose uniformity.
Quality Concern
No Verifiable Lot Documentation
The listed research text specifies avoiding products with generic, undated, internally generated, or unverifiable purity claims, especially where prescription-only supply chains are bypassed.
Research Citations
Modafinil for the treatment of pathological sleepiness in narcolepsy: a randomized, double-blind, placebo-controlled study US Modafinil in Narcolepsy Multicenter Study Group, 2000, JAMA